Principal Financial Group
SGMO

Principal Financial Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Principal Financial Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,083
Closed -$4.69K – 2387
2024
Q2 		$4.69K Sell
13,083
-39,522
-75% -$21.4K ﹤0.01% 2361
2024
Q1 		$35.3K Buy
52,605
+2,157
+4% +$1.56K ﹤0.01% 2365
2023
Q4 		$27.4K Sell
50,448
-3,556
-7% -$1.64K ﹤0.01% 2371
2023
Q3 		$32.4K Buy
54,004
+3,115
+6% +$3.33K ﹤0.01% 2379
2023
Q2 		$66.2K Buy
50,889
+11,784
+30% +$16.1K ﹤0.01% 2339
2023
Q1 		$68.8K Buy
39,105
+4,271
+12% +$12.2K ﹤0.01% 2348
2022
Q4 		$109K Buy
34,834
+4,544
+15% +$17.6K ﹤0.01% 2280
2022
Q3 		$149K Buy
30,290
+6,998
+30% +$35.9K ﹤0.01% 2259
2022
Q2 		$97K Sell
23,292
-13,690
-37% -$59.2K ﹤0.01% 2396
2022
Q1 		$215K Buy
36,982
+458
+1% +$2.72K ﹤0.01% 2319
2021
Q4 		$273K Sell
36,524
-15,347
-30% -$133K ﹤0.01% 2273
2021
Q3 		$467K Buy
51,871
+551
+1% +$5.45K ﹤0.01% 2188
2021
Q2 		$614K Sell
51,320
-4,565
-8% -$51.7K ﹤0.01% 2158
2021
Q1 		$700K Sell
55,885
-2,386
-4% -$32.2K ﹤0.01% 2069
2020
Q4 		$909K Buy
58,271
+17,305
+42% +$203K ﹤0.01% 1964
2020
Q3 		$387K Sell
40,966
-2,807
-6% -$30.4K ﹤0.01% 2072
2020
Q2 		$392K Buy
43,773
+11,807
+37% +$110K ﹤0.01% 2029
2020
Q1 		$204K Buy
31,966
+1,371
+4% +$10.2K ﹤0.01% 2056
2019
Q4 		$256K Sell
30,595
-1,056
-3% -$9.71K ﹤0.01% 2085
2019
Q3 		$286K Buy
31,651
+3,459
+12% +$38.8K ﹤0.01% 2062
2019
Q2 		$304K Sell
28,192
-1,213
-4% -$12.9K ﹤0.01% 2061
2019
Q1 		$281K Buy
29,405
+1,303
+5% +$13.3K ﹤0.01% 2052
2018
Q4 		$322K Sell
28,102
-54,917
-66% -$682K ﹤0.01% 2010
2018
Q3 		$1.41M Buy
83,019
+5,620
+7% +$85.4K ﹤0.01% 1795
2018
Q2 		$1.1M Buy
77,399
+22,919
+42% +$381K ﹤0.01% 1833
2018
Q1 		$1.03M Buy
54,480
+3,910
+8% +$83.6K ﹤0.01% 1819
2017
Q4 		$829K Buy
50,570
+39,496
+357% +$588K ﹤0.01% 1875
2017
Q3 		$166K Sell
11,074
-1,904
-15% -$21K ﹤0.01% 2123
2017
Q2 		$114K Buy
12,978
+832
+7% +$5.34K ﹤0.01% 2172
2017
Q1 		$63K Hold
12,146
– – ﹤0.01% 2166
2016
Q4 		$37K Hold
12,146
– – ﹤0.01% 2211
2016
Q3 		$56K Hold
12,146
– – ﹤0.01% 2137
2016
Q2 		$70K Hold
12,146
– – ﹤0.01% 2118
2016
Q1 		$73K Buy
12,146
+373
+3% +$2.24K ﹤0.01% 2103
2015
Q4 		$107K Hold
11,773
– – ﹤0.01% 2102
2015
Q3 		$66K Sell
11,773
-195
-2% -$1.61K ﹤0.01% 2120
2015
Q2 		$133K Buy
11,968
+1,011
+9% +$13K ﹤0.01% 2105
2015
Q1 		$172K Sell
10,957
-16
-0.1% -$248 ﹤0.01% 2051
2014
Q4 		$167K Sell
10,973
-3,037
-22% -$36.9K ﹤0.01% 2062
2014
Q3 		$151K Hold
14,010
– – ﹤0.01% 2073
2014
Q2 		$214K Sell
14,010
-5,023
-26% -$72.3K ﹤0.01% 2065
2014
Q1 		$344K Buy
19,033
+1,951
+11% +$37.6K ﹤0.01% 1952
2013
Q4 		$237K Sell
17,082
-9,921
-37% -$114K ﹤0.01% 2093
2013
Q3 		$283K Sell
27,003
-1,769
-6% -$17.6K ﹤0.01% 1979
2013
Q2 		$225K Buy
+28,772
New +$251K ﹤0.01% 2033

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Principal Financial Group's SGMO Position: Q3 2024 in Review

Principal Financial Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 13,083 shares — an estimated $4.69K sold.

Principal Financial Group first reported a position in SGMO in Q2 2013 and held it in 45 quarters. The position peaked at $1.41M in Q3 2018. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Principal Financial Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 13,083 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $4.69K.
  • Principal Financial Group first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 45 quarters.
  • Principal Financial Group's SANGAMO THERAPEUTICS INC position peaked at $1.41M in Q3 2018.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.